RxDoctor Payments Data

Teresa Muller, APRN

Family · Sioux City, IANPI 1033281613

Payments from drug & device makers

$927in general payments, 2019–2025

Across 39 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$153
  • Abbott$141
  • Johnson & Johnson$110
  • E.r. Squibb & Sons, L.L.C.$77
  • Pfizer$69
  • Scpharmaceuticals Inc.$62
  • plus $315 from 11 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$927 in reported general payments places this provider in the 75th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$69,945
Medicare patients
737
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban325$206,008
XareltoRivaroxaban140$92,060
JardianceEmpagliflozin44$32,096
BrilintaTicagrelor42$23,609
FarxigaDapagliflozin Propanediol28$19,525
EntrestoSacubitril/Valsartan18$14,581
Repatha SureclickEvolocumab17$9,640
Praluent PenAlirocumab12$5,891
Metoprolol Succinate492$3,966
SotalolSotalol Hcl135$1,647
Atorvastatin Calcium280$1,460
Rosuvastatin Calcium144$1,257
Ezetimibe100$1,175
Midodrine Hcl13$1,172
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$206,008325 claims
Johnson & JohnsonXarelto$110$92,060140 claims
AstraZenecaBrilinta, Farxiga$11$43,13470 claims
Boehringer IngelheimJardiance$34$32,09644 claims
NovartisEntresto$53$14,58118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,268 family providers in Iowa.

Other family in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →